Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M 23 January
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants 20 January
